Chronic myeloid leukemia (CML) is a chronic myeloproliferative disorder (MPD) characterized by the presence of the Philadelphia (Ph) chromosome in abnormal pluripotent bone marrow stem cells in more than 90% of patients. The Ph chromosome is the result of a chromosomal translocation t(9;22)(q34;q11) leading to a BCR-ABL chimeric gene, essential in CML pathogenesis. 1 In addition, the BCR-ABL rearrangement can be detected in 40-50% of Ph-negative CML cases by means of reverse transcriptase polymerase chain reaction (PCR) techniques. 2 The clinical course and outcome of these patients are similar to Ph chromosome-positive CML patients. However, the Ph-negative, BCR-ABL rearrangement-negative CML comprises a heterogeneous group of patients with a more aggressive disease and a worse prognosis. [3] [4] [5] Atypical chronic myeloid leukemia (aCML) based on the new WHO classification is a leukemic disorder that demonstrates myelodysplastic as well as myeloproliferative features at the time of initial diagnosis. 6 Clinical manifestations include an increasing leukemia burden with leukocytosis, pronounced organomegaly, extramedullary infiltrates and eventual bone marrow failure leading to anemia and thrombocytopenia, without evidence of overt acute transformation. [7] [8] [9] Thrombocytopenia and marked anemia are poor prognostic factors. In approximately 25-40% of patients, aCML evolves to acute leukemia, whereas the remainder die of marrow failure with a median survival time of less than 20 months with conventional therapy. [10] [11] [12] To date only one case report on the outcome of allogeneic hematopoietic stem cell transplantation (HSCT) in a patient with aCML has been published. 13 Therefore, the aim of this study was to evaluate the outcome of HSCT in patients with aCML.
Patients and methods

Patient and transplant characteristics
We performed a retrospective, single-center study. Patient and transplant characteristics are summarized in Table 1 . Details of conditioning regimen, GVHD prophylaxis of patients, and G-CSF stimulation of donors were published earlier.
14 The stem cell source was bone marrow in three cases and peripheral blood in six cases. Four out of the nine patients had an unrelated donor. Seven donors were HLA identical at the A, B, DRB1, and DQB1 loci with their respective recipients, one donor had a DQ mismatch with his recipient, and one donor was a syngeneic twin. At the HLA-C locus four donors had a mismatch with the recipient. DNA-based typing at the HLA-A and HLA-B levels was performed in six (67%) of nine patients by PCRsequence-specific primers (PCR-SSP). In the remaining patients (33%), HLA-A and HLA-B antigen were determined by conventional serologic methods confirmed by one-dimensional isoelectric focusing (1D-IEF). HLA-C antigen typing was performed by conventional serologic methods (44%) or by PCR-SSP (56%). DRB1/DQB1 antigens were assessed in all patients by high-resolution molecular genetic typing (PCR-SSP). HLA typing of all donors was originally performed at the donor center and was confirmed by a second analysis prior to transplantation.
Diagnostic criteria for aCML
For diagnosis of aCML the following criteria had to be fulfilled according to the WHO classification: 6 (a) peripheral blood leukocytosis due to increased numbers of mature and immature neutrophils, (b) prominent dysgranulopoiesis, (c) no Ph chromosome or BCR/ABL fusion gene, (d) neutrophil precursors (promyelocytes, myelocytes, metamyelocytes) X10% of white blood cells (WBCs), (e) no or minimal absolute basophilia (basophils o2% of WBCs), (f) no or minimal absolute monocytosis (monocytes o10% of WBCs), (g) hypercellular bone marrow biopsy with granulocytic proliferation and granulocytic dysplasia, with or without dysplasia in the erythroid and megakaryocytic lineages, (h) fewer than 20% blasts in the blood or bone marrow.
When these criteria are met in the absence of features consistent with the diagnosis of chronic myeloproliferative syndromes such as polycythemia vera, essential thrombocythemia, idiopathic myelofibrosis, chronic neutrophilic leukemia and chronic myelomonocytic leukemia or chronic myeloproliferative syndrome with hypereosinophilia they indicate a diagnosis of aCML.
Clinical evaluation
Acute GVHD was graded according to standard criteria. 15 Chronic GVHD was assessed in patients alive after day 90. Transplant-related mortality (TRM) was defined as death with no relapse. Disease-free survival was defined as survival without hematologic relapse.
Chimerism analysis
Chimerism analyses of male patients with female donors were performed by PCR amplification of Y-chromosomespecific nucleotide sequences as published earlier. 16 The chimerism of patients with sex-matched donors was analyzed by VNTR-PCR as published earlier 16 and simultaneously by single-nucleotide polymorphism (SNP) real-time PCR as published by Alizadeh et al. 17 All chimerism studies were by default performed on peripheral WBCs and marrow buffy coat cells.
Definition of relapse
Hematologic relapse was diagnosed on the basis of standard hematologic criteria.
Statistics
Cumulative estimates were calculated using the KaplanMeier method. 18 Only patients surviving more than 30 days were included in the analysis of acute GVHD. A minimum of 90 days of follow-up was the criterion for chronic GVHD.
Ethics
All aspects of this retrospective study were approved by the Institutional Review Board on Medical Ethics at the University Hospital of Essen. 
Results
Clinical presentation at diagnosis
For these patients the median Karnofsky score for clinical performance status at initial diagnosis was 90% with a range from from 60 to 100%. The predominant clinical sign was splenomegaly with an average spleen size of 17.4 cm below the left costal margin (range, 13-28). The mean leukocyte count was 56.4 Â 10 9 /l (range, 2.7-235); the mean hemoglobin level was 11.2 g/dl and the mean platelet numbers were 500 Â 10 9 /l (range, 26-1215) The full WBC differential showed prominence of immature granulocytes (mean 22.3%) including a blast percentage ranging from 0 to 7. There were no increases in basophil or monocyte counts above the limits given by the WHO classification for aCML. Bone marrow histopathology demonstrated hypercellularity with dysplasia in different cell lineages and an increased myeloid:erythroid ratio with left shifted maturation.
Clinical course and outcome post transplant
One patient was transplanted with a dose-reduced conditioning regimen due to his age (61 years). Another patient who was 59 years at the time of transplantation received campath-1H (cumulative dose 100 mg) in order to prevent severe acute GHVD. This patient suffered from cerebral toxoplasmosis and died from sepsis 273 days post transplant.
Eight of nine study patients treated by allogeneic (n ¼ 8) or syngeneic (n ¼ 1) transplantation were alive at the time of analysis with a median follow-up of 55 months (range 9-118 months). The median day for peripheral leukocyte and platelet engraftment was day þ 16. Hematologic relapse with more than 20% lymphoid blasts (bone marrow and peripheral blood) occurred in one patient with advanced disease 19 months after syngeneic transplant. This patient was successfully retransplanted 11 months after this relapse (30 months after his first transplantation) with peripheral blood stem cells from the original donor after receiving a conditioning therapy with Dexa-BEAM (dexamethasone, BCNU 300 mg/m and SNP real-time PCR (in six patients) revealed a complete chimerism status 3 (n ¼ 8) and 12 months (n ¼ 6) post transplant in all examined patients who received an allogeneic transplant. All patients suffered from acute as well as chronic GVHD. Extensive chronic GVHD occurred in three patients and was characterized by a multitude of manifestations including generalized or localized skin involvement, liver histology showing chronic aggressive hepatitis with bridging necrosis or cirrhosis, bronchiolitis obliterans, ocular involvement and involvement of the oral mucosa. It was controlled by prolonged immunosuppressive treatment with cyclosporine, prednisone, mycophenolate mofetil and involved various supportive care measures (antimicrobial prophylaxis, PUVA and others). Two of the three patients are currently on low dose prednisolone; in the third patient the immunosuppressive medication was discontinued. The current Karnofsky score of these patients is 80, 90 and 100% and does not differ significantly from that of the other patients (median Karnofsky score post transplant: 90%). The five patients suffering from limited chronic GVHD are currently working but the patients with extensive chronic GVHD had to give up work ( Table 2) .
Discussion
The exact incidence of aCML is not known, but there are probably only one or two cases for every 100 cases of Phpositive CML. 6 Studies in the early 1990s reported a poor outcome with conventional chemotherapy including hydroxyurea, interferon-a and busulfan. 7, 9, 11 Morevoer, since the new tyrosine kinase inhibitor imatinib has a selective activity against Abl and Bcr-Abl oncoproteins, 20 it is unlikely to be useful in treating aCML. It was not effective in aCML according to a report of Cortes et al. 19 Therefore, allogeneic HSCT remained the only curative option for these patients. In this study we show the good curative potential associated with an acceptable transplant-related morbidity of HSCT for aCML.
We found a high incidence of acute and chronic GVHD with only slightly higher GVHD grades as usually seen in BCR-ABL-positive CML patients after transplantation. Acute GVHD grades II-IV occurred in five of eight aCML patients (62.5%), which was comparable to the incidence of acute GVHD grades II-IV of 40-60% in BCR-ABLpositive CML patients with HLA-identical sibling donors. 16 However, three of the five aCML patients with acute GVHD suffered from acute GVHD grade III. Chronic GVHD was seen in all aCML patients who received an allogeneic transplantation (extensive disease in three cases and limited disease in five cases) compared to 50-60% after transplantation for BCR-ABL-positive CML with HLA identical sibling donors at our institution as published earlier. 16 Four of the eight patients had received transplants from HLA-compatible unrelated donors, which may have influenced the incidence of acute and chronic GVHD as shown earlier. 20 In all patients including those with extensive disease GVHD could be controlled by immunosuppressive medication.
Though the Gratwohl score was established only for the risk assessment of patients with Ph-postive CML, we applied it to the nine patients. The median value was 2.5, which predicted an overall survival of 50-65% after 5 years. 21 In contrast to this, we had eight survivors among our nine aCML patients with a median follow-up of 55 months post transplant (resembling an estimated survival rate of 89% after 9 years). BCR-ABL-positive CML patients who were transplanted with unmanipulated bone marrow or peripheral blood stem cells with HLA-identical sibling donors had an estimated overall survival rate of 60-70% at our institution as published earlier. 16 In comparison we therefore found a higher estimated survival rate for aCML than for BCR-ABL-positive CML. However, it should be noted that due to the number of patients our data should be interpreted with caution and the use of the Gratwohl score is may not be valid in patients with aCML.
Our results suggest that the outcome of allogeneic HSCT for aCML may not be worse than for BCR-ABL-positive CML. Thus allogeneic HSCT probably remains the best therapeutic option for these patients.
